Literature DB >> 20851082

HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease virus antigens in mammalian cells can be used for genetic immunization.

Alejandra D'Antuono1, Andrea S Laimbacher, Jose La Torre, Virginia Tribulatti, Carina Romanutti, Patricia Zamorano, Valeria Quattrocchi, Elisabeth M Schraner, Mathias Ackermann, Cornel Fraefel, Nora Mattion.   

Abstract

HSV-1 amplicon vectors encoding heterologous antigens were capable to mediate in situ generation of protein synthesis and to generate a specific immune response to the corresponding antigens. In this study, foot-and-mouth disease (FMD) virus antigens were used to generate a genetic vaccine prototype. The amplicons were designed to provide a high safety profile as they do not express any HSV-1 genes when packaged using a helper virus-free system, and they are able to encapsidate several copies of the transgene or allow the simultaneous expression of different genes. Virus-like particles were produced after cell processing of the delivered DNA. Inoculation of mice with 5 × 10(5) transducing units of amplicon vectors resulted in FMDV-specific humoral responses in the absence of adjuvants, which were dependent on the in situ de novo production of the vector-encoded antigens. Challenge of mice vaccinated with these amplicons with a high dose of live virus, resulted in partial protection, with a significant reduction of viremia. This work highlights the potential use of a HSV-1 amplicon vector platform for generation of safe genetic vaccines.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851082     DOI: 10.1016/j.vaccine.2010.09.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice.

Authors:  Andrea S Laimbacher; Laura E Esteban; Alejandro A Castello; Juan C Abdusetir Cerfoglio; Marcelo H Argüelles; Graciela Glikmann; Alejandra D'Antuono; Nora Mattion; Mabel Berois; Juan Arbiza; Monika Hilbe; Elisabeth M Schraner; Michael Seyffert; Christiane Dresch; Alberto L Epstein; Mathias Ackermann; Cornel Fraefel
Journal:  Mol Ther       Date:  2012-06-19       Impact factor: 11.454

2.  Induction of humoral responses to BHV-1 glycoprotein D expressed by HSV-1 amplicon vectors.

Authors:  Andrea Maria Blanc; Mabel Beatriz Berois; Lorena Magalí Tomé; Alberto L Epstein; Juan Ramón Arbiza
Journal:  J Vet Sci       Date:  2012-03       Impact factor: 1.672

3.  A Recombinant Adenovirus Expressing P12A and 3C Protein of the Type O Foot-and-Mouth Disease Virus Stimulates Systemic and Mucosal Immune Responses in Mice.

Authors:  Yinli Xie; Peng Gao; Zhiyong Li
Journal:  Biomed Res Int       Date:  2016-07-10       Impact factor: 3.411

4.  Transfer of Anti-Rotavirus Antibodies during Pregnancy and in Milk Following Maternal Vaccination with a Herpes Simplex Virus Type-1 Amplicon Vector.

Authors:  Anita F Meier; Mark Suter; Elisabeth M Schraner; Bruno M Humbel; Kurt Tobler; Mathias Ackermann; Andrea S Laimbacher
Journal:  Int J Mol Sci       Date:  2017-02-16       Impact factor: 5.923

5.  Rotavirus viroplasm fusion and perinuclear localization are dynamic processes requiring stabilized microtubules.

Authors:  Catherine Eichwald; Francesca Arnoldi; Andrea S Laimbacher; Elisabeth M Schraner; Cornel Fraefel; Peter Wild; Oscar R Burrone; Mathias Ackermann
Journal:  PLoS One       Date:  2012-10-23       Impact factor: 3.240

6.  Requirements for improved vaccines against foot-and-mouth disease epidemics.

Authors:  Jong-Hyeon Park
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

7.  Transient gene expression in serum-free suspension-growing mammalian cells for the production of foot-and-mouth disease virus empty capsids.

Authors:  Ana Clara Mignaqui; Vanesa Ruiz; Sylvie Perret; Gilles St-Laurent; Parminder Singh Chahal; Julia Transfiguracion; Ayelén Sammarruco; Victoria Gnazzo; Yves Durocher; Andrés Wigdorovitz
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

8.  U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis.

Authors:  Francesca Caccuri; Roberto Ronca; Andrea S Laimbacher; Angiola Berenzi; Nathalie Steimberg; Federica Campilongo; Pietro Mazzuca; Arianna Giacomini; Giovanna Mazzoleni; Anna Benetti; Elisabetta Caselli; Marco Presta; Dario Di Luca; Cornel Fraefel; Arnaldo Caruso
Journal:  Oncotarget       Date:  2017-07-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.